Abstract:We aimed to examine the effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone marrow mesenchymal stem cells (BMSCs) into adipocytes and investigate its effect on bone metabolism. BMSCs were harvested from the femurs and tibias of a rat, then separated, purified, proliferated for 3 generations and differentiated into preosteoblasts for 5 days and 14 days respectively in the presence of osteogenic medium. Thereafter, the preosteoblasts were cultured for 21 days in the presence of adipogenic medium with and without pioglitazone (1 μg/mL). Partially-differentiated osteoblasts were identified by mineralized nodules with Alizarin red S staining. Transdifferentiated adipocytes were identified by Oil Red O staining. Reverse transcription PCR (RT-PCR) was performed to assay the expression levels of osteogenic markers Runx2 and ALP, and an adipogenic marker PPARγ. Those cells cultured for 5 days did not show mineralized nodules as detected by staining of Alizarin red S, while those cultured for 14 days showed dispersed mineralized centers in the form of brown spots, although without obvious red mineralized nodules. After adipogenic transdifferentiation for 21 days, adipose-drops were found in cells of 5CG and 5EG earlier than those of 14CG and 14EG, and the former showed much more adipocytes separately as detected by Oil Red O staining. Whatever the time was 5 days or 14 days of BMSCs osteogenic differentiation, the cells cultured with pioglitazone showed much more adipocytes than those without pioglitazone. Our experiment showed that the less time it took for BMSCs osteogenic differentiation, a stronger ability remained for BMSCs to transdifferentiate into adipocytes. The mRNA expression levels of Runx2 and ALP were decreased by 1.79 and 1.90 times respectively in 5EG (P< 0.05) as compared with 5CG, and that of PPARγ was increased by 1.31 times in 5EG (P<0.05) as compared with 5CG. The mRNA expression levels of Runx2 and ALP were decreased by 1.45 and 1.54 times respectively in 14EG (P<0.05) as compared with 14CG, and that of PPARγ was increased by 1.39 times in 14EG (P<0.05) as compared with 14CG. It was concluded that pioglitazone stimulated the transdifferentiation of BMSCs into adipocytes. These observations provided a potential mechanism of imbalance in thiazolidinedione induced bone metabolism.

Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells

Effect and Mechanism of Pioglitazone on Cell Growth in Human Gastric Cancer Cells

Effect of Ligand Troglitazone on Peroxisome Proliferator-Activated Receptor Gamma Expression and Cellular Growth in Human Colon Cancer Cells

Effect of pioglitszone and ATRA on expression of PPARγ mRNA of gastric cancer SGC-7901 cells

Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling

Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits glioma cell growth mediated by β-catenin

Troglitazone Inhibits Cell Proliferation by Attenuation of Epidermal Growth Factor Receptor Signaling Independent of Peroxisome Proliferator-Activated Receptor Γ

PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.

PPARγ Ligands Inhibit Cholangiocarcinoma Cell Growth Through P53-Dependent GADD45 and P21waf1/cip1 Pathway

Effect of Pioglitazone on Transdifferentiation of Preosteoblasts from Rat Bone Mesenchymal Stem Cells into Adipocytes

Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway

Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse

Peroxisome Proliferator-Activated Receptor Gamma Agonist Pioglitazone Inhibits Beta-Catenin-Mediated Glioma Cell Growth And Invasion

Activation of PPARγ inhibits cells growth of colorectal carcinoma via inducing cell apoptosis and cell cycle arrest

Protective effect of pioglitazone on islet cell apoptosis induced by proinflammatory cytokines

[Effects of Peroxisome Proliferator-Activated Receptor-Gamma Ligand Troglitazone on Colon Cancer Cell Growth].

Pioglitazone Modulates the Proliferation and Apoptosis of Vascular Smooth Muscle Cells Via Peroxisome Proliferators-Activated Receptor-Gamma

15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells

The Effects of Flavonoid Compound from Agrimonia Pilosa Ledeb on Promotting 3T3-L1 Preadipocytes Differentiation by Activating PPARγ Partially

Inhibition of Cancer Cell Proliferation by PPARγ is Mediated by a Metabolic Switch That Increases Reactive Oxygen Species Levels.

Troglitazone Inhibits Rat Pituitary Adenoma GH3 Cell Growth by Activating Peroxisome Proliferator-Activated Receptor-Gamma to Suppress Cyclin DI Transcription